ArticleFrontiers in neurology2025
Comprehensive analysis of partial confounding clinical symptoms and treatment options of botulism: a case series.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Botulinum neurotoxin: from molecular pathogenesis to emerging countermeasures.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To examine the clinical presentations, and therapeutic principles of botulism, with the goal of improving physicians' understanding of the condition and refining treatment strategies. Method: A retrospective analysis was carried out on the clinical data of 8 patients with botulism, encompassing age, gender, etiology, delay diagnosis time, course of disease, clinical manifestations, auxiliary examinations, and treatment. Results: Among the 8 cases, 5 were female and 3 male, with the age ranging from 14 to 60 years. 5 cases were of iatrogenic poisoning, and 3 were of foodborne poisoning. Besides the classical clinical manifestations, some patients had atypical symptoms like intestinal obstruction, unilateral involvement, and consciousness disorder. Among the 8 cases, 6 had abnormal electrophysiological examination results. 6 patients had a delayed diagnosis of over 7 days, with disease course from 7 to 115 days, and 7 received treatment. All patients received symptomatic and supportive treatment. Moreover, 4 received invasive respiratory support, 3 received intravenous immunoglobulin injection, 1 received plasma exchange therapy, and 1 received antitoxin therapy. All patients were discharged with normal cranial nerve function, gastrointestinal function, muscle strength, and tone. Conclusion: Patients with botulism may exhibit atypical clinical symptoms, necessitating heightened vigilance from physicians. Neurophysiological studies are integral to the diagnostic process. Furthermore, symptomatic supportive treatment is essential for patients whose diagnosis has been delayed beyond 7 days. In conclusion, a comprehensive understanding of the clinical features, differential diagnostic criteria, and therapeutic options for botulism is essential for reducing disease duration, optimizing patient outcomes, and enhancing treatment efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.